FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness

Inability to chew Arymo ER tablet helps Egalet overcome questions about clinical meaningfulness of human oral abuse study results; advisors also back intranasal, intravenous deterrence claims.